MARX Biotech Co., Ltd.(TW:7731)
NT$4.26-0.09 (-2.07%)
TW:7731
MARX Biotech Co., Ltd. financials statements
NT$4.26
At close:-0.09 (-2.07%)
MARX Biotech Co., Ltd. (7731) Ratios
MARX Biotech Co., Ltd. Ratios
TW:7731's free cash flow for Q2 2026 was NT$-79.63M. For the 2026 fiscal year, TW:7731's free cash flow was decreased by NT$-1.44M and operating cash flow was NT$-78.20M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.78 | 1.34 | 3.40 | 2.31 | 3.59 |
| Quick Ratio | 1.42 | 0.80 | 2.70 | 2.03 | 3.23 |
| Cash Ratio | 0.11 | 0.25 | 1.51 | 0.67 | 0.66 |
| Solvency Ratio | 0.13 | -0.16 | -0.08 | 0.11 | 0.59 |
| Operating Cash Flow Ratio | -0.48 | -0.35 | -0.14 | 0.28 | -0.68 |
| Short-Term Operating Cash Flow Coverage | -1.04 | -1.09 | 0.00 | 1.14 | 0.00 |
| Net Current Asset Value | NT$ 74.93M | NT$ -72.65M | NT$ 241.19M | NT$ 53.61M | NT$ 62.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.37 | 0.38 | 0.00 | 0.13 | 0.02 |
| Debt-to-Equity Ratio | 0.86 | 1.10 | 0.01 | 0.23 | 0.03 |
| Debt-to-Capital Ratio | 0.46 | 0.52 | 0.01 | 0.19 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.31 | 0.40 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.32 | 2.91 | 1.35 | 1.70 | 1.39 |
| Debt Service Coverage Ratio | 0.48 | -0.76 | -21.37 | 0.48 | 309.04 |
| Interest Coverage Ratio | -10.19 | -35.02 | -38.54 | 7.88 | 307.20 |
| Debt to Market Cap | 0.13 | 0.08 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.68 | 0.55 | 0.00 | 0.08 | 0.02 |
| Net Debt to EBITDA | 3.02 | -2.62 | 14.35 | -1.99 | -0.74 |
| Profitability Margins | |||||
| Gross Profit Margin | 62.06% | 69.56% | 74.02% | 76.11% | 76.63% |
| EBIT Margin | 11.24% | -15.40% | -5.21% | 4.54% | 18.13% |
| EBITDA Margin | 14.31% | -12.49% | -3.63% | 6.30% | 19.48% |
| Operating Profit Margin | -21.93% | -12.52% | -4.94% | 0.81% | 15.42% |
| Pretax Profit Margin | 9.09% | -15.76% | -5.34% | 4.43% | 18.08% |
| Net Profit Margin | 6.75% | -15.66% | -4.46% | 2.56% | 14.12% |
| Continuous Operations Profit Margin | 6.63% | -15.66% | -4.46% | 2.56% | 14.12% |
| Net Income Per EBT | 74.29% | 99.38% | 83.40% | 57.70% | 78.08% |
| EBT Per EBIT | -41.43% | 125.89% | 108.04% | 546.33% | 117.22% |
| Return on Assets (ROA) | 5.15% | -13.24% | -3.27% | 2.74% | 15.13% |
| Return on Equity (ROE) | 11.94% | -38.54% | -4.41% | 4.66% | 21.00% |
| Return on Capital Employed (ROCE) | -26.57% | -18.08% | -4.88% | 1.46% | 22.64% |
| Return on Invested Capital (ROIC) | -15.23% | -14.51% | -4.05% | 0.69% | 17.36% |
| Return on Tangible Assets | 5.61% | -15.14% | -3.59% | 2.74% | 15.13% |
| Earnings Yield | 1.87% | -2.73% | -0.29% | 0.18% | 1.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.70 | 5.08 | 2.87 | 2.01 | 1.59 |
| Payables Turnover | 4.76 | 2.12 | 3.18 | 5.03 | 3.61 |
| Inventory Turnover | 2.18 | 1.15 | 1.08 | 2.20 | 2.53 |
| Fixed Asset Turnover | 3.04 | 2.85 | 68.11 | 23.41 | 38.07 |
| Asset Turnover | 0.76 | 0.85 | 0.73 | 1.07 | 1.07 |
| Working Capital Turnover Ratio | 3.69 | 3.57 | 1.96 | 1.87 | 0.00 |
| Cash Conversion Cycle | 305.31 | 218.39 | 351.22 | 274.31 | 272.95 |
| Days of Sales Outstanding | 214.91 | 71.87 | 126.98 | 181.27 | 229.61 |
| Days of Inventory Outstanding | 167.11 | 318.74 | 339.17 | 165.68 | 144.35 |
| Days of Payables Outstanding | 76.71 | 172.22 | 114.92 | 72.64 | 101.01 |
| Operating Cycle | 382.02 | 390.61 | 466.14 | 346.95 | 373.96 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.31 | -0.21 | -0.03 | 0.07 | -0.12 |
| Free Cash Flow Per Share | -0.34 | -0.64 | -0.03 | 0.06 | -0.12 |
| Dividend Paid and CapEx Coverage Ratio | -10.53 | -0.49 | -1.70 | 1.42 | -355.49 |
| Capital Expenditure Coverage Ratio | -10.53 | -0.49 | -8.12 | 16.44 | -355.49 |
| Operating Cash Flow Coverage Ratio | -0.48 | -0.39 | -7.51 | 0.83 | -7.94 |
| Operating Cash Flow to Sales Ratio | -0.23 | -0.17 | -0.05 | 0.10 | -0.17 |
| Free Cash Flow Yield | -7.11% | -9.20% | -0.35% | 0.69% | -1.34% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 53.38 | -36.58 | -349.42 | 452.50 | 90.50 |
| Price-to-Sales (P/S) Ratio | 3.60 | 5.73 | 15.55 | 14.15 | 12.77 |
| Price-to-Book (P/B) Ratio | 6.37 | 14.10 | 15.38 | 25.77 | 19.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.07 | -10.87 | -283.79 | 145.68 | -74.42 |
| Price-to-Operating Cash Flow Ratio | -15.40 | -33.04 | -318.73 | 136.82 | -74.63 |
| Price-to-Earnings Growth (PEG) Ratio | -0.36 | -0.06 | 1.52 | -5.66 | 0.00 |
| Enterprise Value Multiple | 28.20 | -48.48 | -414.03 | 222.61 | 64.85 |
| Enterprise Value | 2.57B | 3.74B | 4.36B | 1.55B | 1.23B |
| EV to EBITDA | 28.20 | -48.48 | -414.03 | 222.61 | 64.85 |
| EV to Sales | 4.04 | 6.06 | 15.03 | 14.02 | 12.63 |
| EV to Free Cash Flow | -15.76 | -11.50 | -274.29 | 144.39 | -73.58 |
| EV to Operating Cash Flow | -17.25 | -34.94 | -308.05 | 135.60 | -73.79 |
| Tangible Book Value Per Share | 0.61 | 0.31 | 0.52 | 0.35 | 0.48 |
| Shareholders’ Equity Per Share | 0.76 | 0.49 | 0.59 | 0.35 | 0.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.27 | 0.01 | 0.17 | 0.42 | 0.22 |
| Revenue Per Share | 1.34 | 1.21 | 0.58 | 0.64 | 0.71 |
| Net Income Per Share | 0.09 | -0.19 | -0.03 | 0.02 | 0.10 |
| Tax Burden | 0.74 | 0.99 | 0.83 | 0.58 | 0.78 |
| Interest Burden | 0.81 | 1.02 | 1.02 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.84 | 0.78 | 0.79 | 0.74 | 0.59 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -2.57 | 1.10 | 0.91 | 4.04 | -1.21 |
Currency in TWD
